NDAORALFOR SOLUTIONPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
VIDEX (didanosine) by Bristol Myers Squibb is [ see clinical pharmacology () ]. First approved in 1991.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX (didanosine) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 1991 for HIV treatment. It works by inhibiting reverse transcriptase, blocking viral replication in HIV-infected patients. The drug represents an early-generation antiretroviral with historical significance in HIV therapy evolution.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating reduced commercial investment and team contraction likely underway.
Mechanism of Action
[ see Clinical Pharmacology () ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
90 enrolled
Sarcoma, KaposiHIV Infections
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
116 enrolled
HIV Infections
A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV
180 enrolled
HIV Infections
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
400 enrolled
HIV Infections
A Study of Efavirenz in Combination With Stavudine and Didanosine
60 enrolled
HIV Infections
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.